Boundless Bio Inc. (BOLD)

Boundless Bio, Inc.'s stock (BOLD) has trended down by 27.92% in the past six months and 56.64% over the past year. The company went public on March 28, 2024, with an IPO of 6,250,000 shares at $16 apiece, raising $100 million. In May 2025, the company announced preliminary Phase 1/2 clinical trial data for BBI-355, which revealed hematological toxicity, leading to its discontinuation as a single agent. Following the clinical trial setbacks in May 2025, the company laid off approximately one-third of its staff to extend its cash runway into the first half of 2028. On August 5, 2025, Boundless Bio reported its second-quarter 2025 financial results, showing a reduction in research and development expenses and reaffirming its cash position. On November 5, 2025, the company reported its third-quarter 2025 financial results and business highlights. On November 24, 2025, Boundless Bio announced its participation in the Piper Sandler 37th Annual Healthcare Conference.

Boundless Bio, Inc.'s products and services do not exhibit traditional demand seasonality. The demand for cancer treatments and diagnostics is generally driven by disease prevalence, clinical trial progress, regulatory approvals, and medical need, rather than seasonal fluctuations.

Boundless Bio, Inc. is a clinical-stage oncology company in the Healthcare sector, specifically in the Biotechnology industry, dedicated to developing cancer therapeutics. The company focuses on addressing the unmet needs of patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA). Its major product candidates and platforms include BBI-355, an ecDNA-directed therapeutic candidate and oral inhibitor of checkpoint kinase 1 (CHK1) in Phase 1/2 clinical trials; BBI-098, a picomolar biochemical inhibition of checkpoint kinase 1; ECHO, an ecDNA diagnostic test; Spyglass platform, a proprietary platform used to identify druggable targets; and BBI-825, an oral inhibitor of ribonucleotide reductase (RNR) which was discontinued as a monotherapy in December 2024; and BBI-940, a development candidate from its kinesin degrader program.

Boundless Bio, Inc. is headquartered in San Diego, California, United States.

Boundless Bio's brand reputation has likely been impacted by the clinical trial data for BBI-355, which indicated a narrow therapeutic window and hematological toxicity, leading to the company stopping further development of BBI-355 as a monotherapy. This setback, coupled with the decision to lay off approximately one-third of its staff in May 2025, would have negatively affected its reputation. Despite these challenges, the company continues to present at healthcare conferences and report on its financial results and pipeline progress, indicating ongoing efforts to maintain its standing. Analyst ratings for BOLD have been mixed, with a consensus rating of "Hold".

Boundless Bio is owned by a mix of institutional shareholders, company insiders, and retail investors. Approximately 42.98% of the company is owned by institutional shareholders, 23.82% by Boundless Bio insiders, and 33.20% by retail investors. Major institutional owners include Fmr Llc, Nextech Invest, Ltd., FDGRX - Fidelity Growth Company Fund, Citadel Advisors Llc, Sectoral Asset Management Inc, Vanguard Group Inc, Wellington Management Group Llp, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, Stonepine Capital Management, LLC, Alyeska Investment Group, L.P., RA CAPITAL MANAGEMENT, L.P., ARCH Venture Fund IX, L.P., Arch Venture Partners, L.P., Vertex Venture Management Pte. Ltd., Redmile Group, Llc, Ensign Peak Advisors, Inc., and BlackRock, Inc. The largest individual shareholder is Keith Crandell, owning 1.18 million shares, representing 5.28% of the company.